Transcat raised to outperform from perform by Oppenheimer
TRNS•Oppenheimer raised its rating on Transcat to outperform from perform.
Related News
DuPont de Nemours: UBS raises target price to $182 from $172
DD•
Trump's midterm trouncing underscores inflation's political poison
SPY•
Erasca, Tango Therapeutics launch Phase 1/2 trial of cancer drug combination
TNGX•
Qualcomm signs major 5G infrastructure deal with SpaceX for Starlink Mobile network
QCOM•
EMCOR Group target price cut to $925 from $1,065 by UBS
EME•